| ReMIND – Discovery Stage ReMIND | Xin Jin | Translational epigenomics: dissecting cell type-specific function of neuropsychiatric risk genes in vivo |
$11,376,314 |
| ReMIND – Discovery Stage ReMIND | Stuart A Lipton | Multiomic Studies of Idiopathic Intellectual Disability and Autism Spectrum Disorder (ID/ASD) |
$17,365,387 |
| Foundation – Discovery Stage Research Projects | Xin Jin | Functional genomics to study cellular convergence across ASD risk genes in neurodevelopment |
$1,575,001 |
| Discovery Research Projects | Stuart A Lipton | Repurposing Aminoadamantane Nitrate Compounds to Inhibit SARS-CoV-2 Viral Activity and to Protect the Brain from Viral-Related Damage |
$150,000 |
| Quest – Discovery Stage Research Projects | Stuart A Lipton | Drug Development of Inhibitors of Inflammation Using Human iPSC-Derived Microglia (hiMG) |
$1,648,969 |
| Quest – Discovery Stage Research Projects | Dr Michael J Bollong | Therapeutics to overcome the differentiation roadblock in Myelodysplastic Syndrome (MDS) |
$1,244,160 |
| Quest – Discovery Stage Research Projects | Luke L Lairson | Improving the efficacy and tolerability of clinically validated remyelination-inducing molecules using developable combinations of approved drugs |
$1,554,126 |
| Quest – Discovery Stage Research Projects | Stuart A Lipton | Drug Development for Autism Spectrum Disorder Using Human Patient iPSCs |
$1,827,576 |
| Quest – Discovery Stage Research Projects | Dr. Jeanne F Loring | Autologous cell therapy for Parkinson’s disease using iPSC-derived DA neurons |
$2,299,786 |
| Clinical Trial Stage Projects | Dr. Kristen A Johnson | Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
| Late Stage Preclinical Projects | Peter G Schultz | Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
| Preclinical Development Awards | Peter G Schultz | Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
| Tools and Technologies III | Dr. Jeanne F Loring | User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
| Conference | Dr. Jeanne F Loring | World Stem Cell Summit |
$30,000 |
| Creativity Awards | James R Williamson | Stem Cell Summer Academy: Creating the Next Generation of Scientists |
$205,122 |
| Early Translational III | Peter G. Schultz | Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis |
$2,559,333 |
| Training Grant I-2 | Peter G. Schultz | Training Grant I |
$1,021,395 |
| Research Training II | Dr. Ulrich Mueller | Training Stem Cell Researchers at the Chemistry-Biology Interface |
$3,697,326 |
| Basic Biology III | Dr. Joel M Gottesfeld | Triplet Repeat Instability in Human iPSCs |
$1,705,494 |
| Basic Biology III | Kristin Baldwin | Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing |
$1,705,500 |
| Early Translational II | Peter G. Schultz | Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,047,249 |
| New Faculty I | Kristin Baldwin | Generating pluripotent cell lines from neurons. |
$2,786,560 |
| New Faculty I | Dr. Sheng Ding Dr. | Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
| Early Translational I | Dr. Martin Friedlander | Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| Early Translational I | Dr. Jeanne F Loring | Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
| Transplantation Immunology | Dr. Nicholas R.J. Gascoigne | Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance |
$1,705,554 |
| Transplantation Immunology | Dr. Jeanne F Loring | Thymus based tolerance to stem cell therapies |
$1,108,921 |
| Tools and Technologies I | Dr. Jeanne F Loring | The Stem Cell Matrix: a map of the molecular pathways that define pluripotent cells |
$1,133,552 |
| Tools and Technologies I | Dr. Carlos F. Barbas Dr. | Development of a novel technology for precise, efficient, and safe genetic modification of stem cells |
$1,138,548 |
| Shared Labs | Sheng Ding PhD | TSRI Center for hESC Research |
$1,440,164 |
| Shared Labs | Dr. Jeanne F Loring | TSRI Center for hESC Research |
$3,725,070 |
| New Cell Lines | Dr. Sheng Ding Dr. | Derivation of New ICM-stage hESCs |
$936,973 |
| SEED Grant | Peter G. Schultz | A Chemical Approach to Stem Cell Biology |
$748,944 |
